Exposure to In Utero Chemotherapy Did Not Affect Children’s Development, Behavior

Article
Conference|Miami Breast Cancer Conference (MBCC)

In this video we discuss two poster presentations on childhood development and behavior after in utero exposure to chemotherapy for maternal cancer in pregnancy.

In this video from the 32nd Annual Miami Breast Cancer Conference, Elyce Cardonick, MD, maternal fetal specialist at the Cooper Health System, discusses two poster presentations on childhood development and behavior after in utero exposure to chemotherapy for maternal cancer in pregnancy.

Recent Videos
Trials at scale can be conducted in middle-income, low-middle-income, and even lower-income countries if you organize a trial ecosystem.
Immunotherapy-based combinations may elicit a synergistic effect that surpasses monotherapy outcomes among patients with muscle-invasive bladder cancer.
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Point-of-care manufacturing, scalable manufacturing, and bringing the cost down [can help].
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
Related Content
Data from the REZILIENT2 trial show meaningful intracranial activity in patients with NSCLC harboring EGFR exon 20 insertions or other uncommon mutations.

Zipalertinib Yields Early Activity in EGFR+ NSCLC CNS Metastasis Population

Caroline Seymour
October 26th 2025
Article

Data from the REZILIENT2 trial show meaningful intracranial activity in patients with NSCLC harboring EGFR exon 20 insertions or other uncommon mutations.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

ESMO Congress 2025 included a variety of presentations that may change the treatment paradigm in lung cancer, breast cancer, and other types of disease.

ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice

Russ Conroy
October 24th 2025
Article

ESMO Congress 2025 included a variety of presentations that may change the treatment paradigm in lung cancer, breast cancer, and other types of disease.

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Sacituzumab govitecan plus pembrolizumab reduced symptom burden and improved functioning across multiple domains in the KEYNOTE-D19 study.

Patient-Reported Outcomes Support Sacituzumab Govitecan Combo in TNBC

Kristie L. Kahl
October 23rd 2025
Article

Sacituzumab govitecan plus pembrolizumab reduced symptom burden and improved functioning across multiple domains in the KEYNOTE-D19 study.

Approximately half of the patients who received raludotatug deruxtecan in the phase 2/3 REJOICE-Ovarian01 trial achieved an objective response.

Raludotatug Deruxtecan Shows Promise in Platinum-Resistant Ovarian Cancer

Jason M. Broderick
October 21st 2025
Article

Approximately half of the patients who received raludotatug deruxtecan in the phase 2/3 REJOICE-Ovarian01 trial achieved an objective response.